Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003824 · ClinicalTrials.gov registry record · Phase 3
S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 3
- Development phase
- 114
- Enrollment target
NCT00003824 is a Phase 3 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 114 participants.
The verdict
NCT00003824, a Phase 3 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 114 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether ciprofloxacin is more effective than cephalexin in preventing cancer recurrence in patients who are undergoing surgery to treat bladder cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of ciprofloxacin with that of cephalexin in preventing recurrence of cancer in patients who are undergoing surgery for bladder cancer.
Interventions
- DRUG Ciprofloxacin
- DRUG cephalexin
- PROCEDURE surgical procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 1999-04 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003824
The ClinicalTrials.gov registry entry for NCT00003824 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ciprofloxacin is the first listed.
NCT00003824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003824 about?
NCT00003824 is a clinical study titled "S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether ciprofloxacin is more effective than cephalexin in preventing cancer recurrence in patients who are undergoing surgery to treat bladder cancer. PURPO...
What is the current status of trial NCT00003824?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 114 participants. The study started on 1999-04. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00003824?
The interventions under investigation include: Ciprofloxacin (DRUG), cephalexin (DRUG), surgical procedure (PROCEDURE).
Who is sponsoring clinical trial NCT00003824?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.